Genelux Corp. Insider Trading

GNLX

Last 12 months

Insiders sold 436K and bought nothing on the open market.

25% of the selling was scheduled in advance under 10b5-1 plans. Director John W Smither sold 35K on Jul 1, 12% of their stake, outside a plan. The last open-market buy by an executive or director was in May 2024.

Net open-market

−436K

0 buys · 23 sales

Under a 10b5-1 plan

25%

of the value sold

Insiders who bought / sold

0 / 6

executives and directors

Last open-market buy

May 2024

May 29, 2024

Get an email when GNLX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 31	Joseph Cappello Chief Technical Officer	SoldNo plan	10,257	$2.74	28K	3.1%	Form 4
Aug 31	Thomas Zindrick President and CEO	SoldNo plan	34,463	$2.67	92K	2.7%	Form 4
Aug 31	Yong Yu Chief Scientific Officer	SoldNo plan	9,683	$2.75	27K	3.6%	Form 4
Aug 4	Yong Yu Chief Scientific Officer	SoldNo plan	653	$2.94	2K	0.2%	Form 4
Aug 4	Joseph Cappello Chief Technical Officer	SoldNo plan	653	$2.95	2K	0.2%	Form 4
Aug 4	Thomas Zindrick President and CEO	SoldNo plan	3,023	$2.95	9K	0.2%	Form 4
Jul 1	John W Smither Director	SoldNo plan	12,000	$2.91	35K	12%	Form 4
Jun 3	Ralph Smalling Head of Regulatory	SoldNo plan	192	$2.93	$563	0.3%	Form 4
Jun 1	John Thomas Director	Sold10b5-1 plan	10,000	$2.98	30K	2.1%	Form 4
May 11	Joseph Cappello Chief Technical Officer	SoldNo plan	605	$2.97	2K	0.4%	Form 4
May 11	Yong Yu Chief Scientific Officer	SoldNo plan	605	$2.97	2K	0.4%	Form 4
May 11	Thomas Zindrick President and CEO	SoldNo plan	2,798	$2.94	8K	0.5%	Form 4
May 11	Ralph Smalling Head of Regulatory	SoldNo plan	270	$2.98	$805	0.4%	Form 4
Mar 24 – 25	Ralph Smalling Head of Regulatory	SoldNo plan 2 parts	585	$2.46 average	1K	0.9%	Form 4
Mar 24	Joseph Cappello Chief Technical Officer	SoldNo plan	906	$2.42	2K	0.6%	Form 4
Mar 24	Yong Yu SVP, Clinical Development	SoldNo plan	906	$2.42	2K	0.6%	Form 4
Mar 24	Thomas Zindrick President and CEO	SoldNo plan	3,582	$2.42	9K	0.7%	Form 4
Mar 2	John Thomas Director	Sold10b5-1 plan	10,000	$2.90	29K	2.0%	Form 4
Aug 21, 2025 – Dec 5, 2025	Ralph Smalling Head of Regulatory	SoldNo plan 4 parts	2,332	$3.75 average	9K	3.3%	Form 4
Dec 1, 2025	John Thomas Director	Sold10b5-1 plan	10,000	$5.00	50K	2.0%	Form 4
Aug 21, 2025 – Nov 17, 2025	Thomas Zindrick President and CEO	SoldNo plan 2 parts	17,182	$3.87 average	66K	3.1%	Form 4
Aug 21, 2025 – Nov 17, 2025	Yong Yu SVP, Clinical Development	SoldNo plan 2 parts	4,192	$3.83 average	16K	2.8%	Form 4
Aug 21, 2025 – Nov 17, 2025	Joseph Cappello Chief Technical Officer	SoldNo plan 3 parts	3,706	$3.88 average	14K	2.3%	Form 4
May 12, 2025	Sean Ryder General Counsel	SoldNo plan	4,475	$2.92	13K	8.6%	Form 4
May 12, 2025	Thomas Zindrick President and CEO	SoldNo plan	10,764	$2.92	31K	5.3%	Form 4
May 12, 2025	Yong Yu VP, Clinical Trial Operations	SoldNo plan	5,579	$2.92	16K	10%	Form 4
May 12, 2025	Joseph Cappello VP, Pharmaceutical Development	SoldNo plan	4,737	$2.92	14K	8.3%	Form 4
May 12, 2025	Ralph Smalling Head of Regulatory	SoldNo plan	1,259	$2.92	4K	3.5%	Form 4
Dec 30, 2024	James L Tyree Director	SoldNo plan	3,460	$2.46	9K	7.0%	Form 4
Dec 16, 2024	Thomas Zindrick President and CEO	SoldNo plan	14,315	$2.34	33K	28%	Form 4
Dec 16, 2024	Lourie S. Zak Chief Financial Officer	SoldNo plan	2,103	$2.34	5K	4.9%	Form 4
Dec 16, 2024	Ralph Smalling Head of Regulatory	SoldNo plan	2,510	$2.34	6K	13%	Form 4
Dec 16, 2024	Joseph Cappello VP, Pharmaceutical Development	SoldNo plan	6,300	$2.34	15K	30%	Form 4

Aug 31No plan
Joseph Cappello
Chief Technical Officer · sold 10,257 at $2.74
28K
3.1% of stake
Aug 31No plan
Thomas Zindrick
President and CEO · sold 34,463 at $2.67
92K
2.7% of stake
Aug 31No plan
Yong Yu
Chief Scientific Officer · sold 9,683 at $2.75
27K
3.6% of stake
Aug 4No plan
Yong Yu
Chief Scientific Officer · sold 653 at $2.94
2K
0.2% of stake
Aug 4No plan
Joseph Cappello
Chief Technical Officer · sold 653 at $2.95
2K
0.2% of stake
Aug 4No plan
Thomas Zindrick
President and CEO · sold 3,023 at $2.95
9K
0.2% of stake
Jul 1No plan
John W Smither
Director · sold 12,000 at $2.91
35K
12% of stake
Jun 3No plan
Ralph Smalling
Head of Regulatory · sold 192 at $2.93
$563
0.3% of stake
Jun 110b5-1 plan
John Thomas
Director · sold 10,000 at $2.98
30K
2.1% of stake
May 11No plan
Joseph Cappello
Chief Technical Officer · sold 605 at $2.97
2K
0.4% of stake
May 11No plan
Yong Yu
Chief Scientific Officer · sold 605 at $2.97
2K
0.4% of stake
May 11No plan
Thomas Zindrick
President and CEO · sold 2,798 at $2.94
8K
0.5% of stake
May 11No plan
Ralph Smalling
Head of Regulatory · sold 270 at $2.98
$805
0.4% of stake
Mar 24 – 25No plan
Ralph Smalling
Head of Regulatory · sold 585 at avg $2.46
1K
0.9% of stake
Mar 24No plan
Joseph Cappello
Chief Technical Officer · sold 906 at $2.42
2K
0.6% of stake
Mar 24No plan
Yong Yu
SVP, Clinical Development · sold 906 at $2.42
2K
0.6% of stake
Mar 24No plan
Thomas Zindrick
President and CEO · sold 3,582 at $2.42
9K
0.7% of stake
Mar 210b5-1 plan
John Thomas
Director · sold 10,000 at $2.90
29K
2.0% of stake
Aug 21, 2025 – Dec 5, 2025No plan
Ralph Smalling
Head of Regulatory · sold 2,332 at avg $3.75
9K
3.3% of stake
Dec 1, 202510b5-1 plan
John Thomas
Director · sold 10,000 at $5.00
50K
2.0% of stake
Aug 21, 2025 – Nov 17, 2025No plan
Thomas Zindrick
President and CEO · sold 17,182 at avg $3.87
66K
3.1% of stake
Aug 21, 2025 – Nov 17, 2025No plan
Yong Yu
SVP, Clinical Development · sold 4,192 at avg $3.83
16K
2.8% of stake
Aug 21, 2025 – Nov 17, 2025No plan
Joseph Cappello
Chief Technical Officer · sold 3,706 at avg $3.88
14K
2.3% of stake
May 12, 2025No plan
Sean Ryder
General Counsel · sold 4,475 at $2.92
13K
8.6% of stake
May 12, 2025No plan
Thomas Zindrick
President and CEO · sold 10,764 at $2.92
31K
5.3% of stake
May 12, 2025No plan
Yong Yu
VP, Clinical Trial Operations · sold 5,579 at $2.92
16K
10% of stake
May 12, 2025No plan
Joseph Cappello
VP, Pharmaceutical Development · sold 4,737 at $2.92
14K
8.3% of stake
May 12, 2025No plan
Ralph Smalling
Head of Regulatory · sold 1,259 at $2.92
4K
3.5% of stake
Dec 30, 2024No plan
James L Tyree
Director · sold 3,460 at $2.46
9K
7.0% of stake
Dec 16, 2024No plan
Thomas Zindrick
President and CEO · sold 14,315 at $2.34
33K
28% of stake
Dec 16, 2024No plan
Lourie S. Zak
Chief Financial Officer · sold 2,103 at $2.34
5K
4.9% of stake
Dec 16, 2024No plan
Ralph Smalling
Head of Regulatory · sold 2,510 at $2.34
6K
13% of stake
Dec 16, 2024No plan
Joseph Cappello
VP, Pharmaceutical Development · sold 6,300 at $2.34
15K
30% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch GNLX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with GNLX

CompareIntrinsic value

ASBPAspire Biopharma Holdings Inc.

$7.27-0.41%20

TCRTAlaunos Therapeutics Inc.

$1.80-3.23%10

ADTXAditxt Inc.

$0.00+33.33%20

TLPHTalphera Inc.

$1.05+0.96%10

SKVISkinvisible Inc.

$0.16+0.00%0

JUNSJupiter Neurosciences Inc.

$2.46+1.23%10

BDPTBioadaptives Inc.

$0.00-5.88%25

LYELLyell Immunopharma, Inc.

$15.43+43.27%10

Held by ETFs

GNLX is in 1 US ETF. The largest of them, with GNLX's weight in each:

iShares Micro-Cap ETFIWC0.02%of the fund

Spot a number that looks wrong? Check it in GNLX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing GNLX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.